Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
VRDN - Viridian Therapeutics, Inc.
Market Cap 791.91M P/E - EPS this Y 27.10% Ern Qtrly Grth -
Income -228.06M Forward P/E -3.75 EPS next Y -8.00% 50D Avg Chg -21.00%
Sales 288k PEG - EPS past 5Y - 200D Avg Chg -31.00%
Dividend N/A Price/Book 3.67 EPS next 5Y - 52W High Chg -53.00%
Recommedations 1.60 Quick Ratio 15.54 Shares Outstanding 76.36M 52W Low Chg 38.00%
Insider Own 0.01% ROA -33.45% Shares Float 57.33M Beta 1.07
Inst Own 94.99% ROE -53.97% Shares Shorted/Prior 10.46M/8M Price 18.36
Gross Margin - Profit Margin - Avg. Volume 796,129 Target Price 39.56
Oper. Margin -100,259.72% Earnings Date Nov 11 Volume 500,040 Change -1.55%
Healthcare | Biotechnology | United States
About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Viridian Therapeutics, Inc. News
12/17/24 Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints
12/16/24 Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen
12/16/24 Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
12/13/24 Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
12/04/24 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/14/24 Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
11/12/24 Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
10/31/24 Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings
09/11/24 Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
09/10/24 Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
09/10/24 Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
09/09/24 Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
08/08/24 Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
07/25/24 Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
06/11/24 Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
05/31/24 Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
05/10/24 Viridian Therapeutics to Participate in Upcoming May Investor Conferences
05/09/24 Viridian Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
05/09/24 Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
05/08/24 Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Fairmount Funds Management LLC Director Director Jan 22 Buy 21.00 476,190 9,999,990 1,839,954 01/24/24
Meisner Lara Chief Legal Officer Chief Legal Officer Jun 02 Sell 24.75 7,500 185,625 29,971 06/06/23
Meisner Lara Chief Legal Officer Chief Legal Officer Jun 02 Option 17.01 7,500 127,575 35,097 06/06/23
Myers Scott Dunseth Chief Executive Offi.. Chief Executive Officer Apr 12 Buy 25.3697 4,000 101,479 259,500 04/12/23
Meisner Lara General Counsel and.. General Counsel and Secretary Mar 09 Sell 29.07 29,971 871,257 03/10/23
Violin Jonathan Chief Executive Off.. Chief Executive Officer Feb 02 Sell 36.8 50,000 1,840,000 480,905 02/07/23
Violin Jonathan Chief Executive Off.. Chief Executive Officer Feb 02 Option 0.15 50,000 7,500 530,905 02/07/23
Meisner Lara General Counsel and.. General Counsel and Secretary Jan 23 Sell 35.66 6,843 244,021 01/25/23
Meisner Lara General Counsel and.. General Counsel and Secretary Jan 23 Option 18.52 6,843 126,732 6,843 01/25/23
Katz Barrett Chief Medical Office.. Chief Medical Officer Jan 13 Sell 37.11 29,000 1,076,190 01/18/23
Katz Barrett Chief Medical Office.. Chief Medical Officer Jan 13 Option 23.03 29,000 667,870 24,853 01/18/23
Katz Barrett Chief Medical Office.. Chief Medical Officer Jan 09 Sell 34.17 60,000 2,050,200 01/11/23
Katz Barrett Chief Medical Office.. Chief Medical Officer Jan 09 Option 23.03 60,000 1,381,800 47,377 01/11/23
Meisner Lara General Counsel and.. General Counsel and Secretary Dec 15 Option 23.03 1,597 36,779 1,297 12/19/22
Meisner Lara General Counsel and.. General Counsel and Secretary Dec 15 Sell 28.26 1,597 45,131 12/19/22
Meisner Lara General Counsel and.. General Counsel and Secretary Dec 12 Option 23.03 16,256 374,376 15,656 12/14/22
Meisner Lara General Counsel and.. General Counsel and Secretary Dec 12 Sell 28.09 16,256 456,631 12/14/22
Fairmount Funds Management LLC - - Aug 17 Buy 23.50 425,531 9,999,978 1,363,764 08/19/22
Violin Jonathan Chief Executive Off.. Chief Executive Officer Jun 01 Sell 12.20 30,000 366,000 480,905 06/02/22
Violin Jonathan Chief Executive Offi.. Chief Executive Officer May 02 Sell 13.04 30,000 391,200 510,905 05/04/22
Violin Jonathan Chief Executive Off.. Chief Executive Officer Apr 01 Sell 18.93 30,000 567,900 540,905 04/05/22
Violin Jonathan Chief Executive Off.. Chief Executive Officer Feb 01 Sell 19.06 30,000 571,800 600,905 02/03/22